Weight gain and antipsychotic medication: Differences between antipsychotic-free and treatment periods

Journal of Clinical Psychiatry

Volumn 62, Issue 9, 2001, Pages 694-700

  Simpson, M M ^a   Goetz, R R ^a   Devlin, M J ^a   Goetz, S A ^a   Walsh, B T ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE MESILATE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; LORAZEPAM; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PIMOZIDE; QUETIAPINE; RISPERIDONE; TIOTIXENE; TRIFLUOPERAZINE;

ADULT; ARTICLE; BODY MASS; CORRELATION FUNCTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSYCHOSIS; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 0034778521     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v62n0906     Document Type: Article

References (43)

1. Clinical effects of clozapine in chronic schizophrenia: Response to treatment and predictors of outcome
2. Risperidone: Efficacy and safety
3. Side effect profiles of new antipsychotic agents
4. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial
5. Weight gain associated with clozapine
6. Long-term treatment of chronic schizophrenic patients with risperidone
7. Weight gain among schizophrenic patients treated with clozapine
8. Clozapine-induced weight gain: Prevalence and clinical relevance
9. Extrapyramidal side effects and tolerability of risperidone: A review
10. Weight gain: Side effect of atypical neuroleptics?
11. The distribution of body mass index among individuals with and without schizophrenia
12. The serotonin blocking properties of antipsychotic drugs
13. Clozapine: A serotonin antagonist?
14. Risperidone (R 64 766), a potent and complete LSD antagonist in drug discrimination by rats
15. 2 pKi values
16. The behavioral pharmacology of olanzapine, a novel "atypical" Antipsychotic agent
17. Clozapine
18. 1 receptors (ex vivo radioreceptor binding studies)
19. Negative symptoms in schizophrenia: Assessment of the effect of risperidone
20. Neuroleptic blockade of the effect of various neurotransmitter substances
21. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography
22. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five year naturalistic study
23. Weight gain, diabetes, and related adverse effects of antipsychotics
24. Clozapine-associated elevation in serum triglycerides
25. Olanzapine increases weight and serum triglyceride levels
26. Elevated levels of insulin, leptin and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses
27. Novel antipsychotics and new onset diabetes
28. Antipsychotics linked to weight gain, diabetes
29. New-onset diabetes mellitus associated with the initiation of quetiapine
30. Effect of clozapinequetiapine combination therapy on weight and glycaemic control
31. Medical hazards of obesity
32. Lithium maintenance treatment of manic-melancholic patients: Its role in the daily routine
33. Weight gain: A side effect of tricyclic antidepressants
34. Psychotropic drug induced weight gain: Mechanism and management
35. Prevalence of obesity in patients receiving depot antipsychotics
36. Weight gain associated with psychotropic drugs
37. Patients' opinions concerning side effects of depot neuroleptics
38. Lithium use and discontinuation in a health maintenance organization
39. Antipsychotic-induced weight gain: A comprehensive research synthesis
40. Weight gain associated with atypical antipsychotics
41. Efficacy of olanzapine: An overview of pivotal clinical trials
42. Bodyweight gain induced by psychotropic drugs: Incidence, mechanisms and management